Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.08%GBPCHF+1.01%AUDUSD-1.00%USDCHF+0.91%GBPCAD+0.77%GBPNZD+0.70%USDCAD+0.70%GBPJPY+0.69%NZDUSD-0.64%EURGBP-0.63%USDJPY+0.60%USDTHB+0.58%EURUSD-0.56%PLNJPY+0.50%EURAUD+0.46%NOKJPY+0.43%AUDJPY-0.42%SGDJPY+0.42%GBPTRY+0.41%AUDNZD-0.36%EURCHF+0.35%AUDCAD-0.33%GBPHKD+0.32%USDTRY+0.29%GBPMXN-0.28%NZDCHF+0.28%CHFJPY-0.27%AUDSGD+0.23%AUDNOK+0.22%CADCHF+0.22%USDILS+0.16%AUDDKK+0.14%EURCAD+0.14%AUDCHF-0.11%NZDMXN-0.11%EURNZD+0.09%USDSGD+0.09%USDCNH-0.09%CADJPY-0.09%USDNOK+0.08%EURCNH+0.08%GBPUSD+0.08%EURSGD+0.08%EURNOK+0.07%NZDCAD+0.06%CHFSGD+0.06%CHFNOK+0.05%USDZAR+0.05%EURJPY+0.04%USDCOP-0.04%GBPSGD+0.04%EURHKD-0.04%EURCZK+0.03%USDHKD+0.03%GBPZAR-0.02%EURZAR+0.02%NZDJPY-0.02%CHFSEK-0.02%USDDKK+0.02%USDMXN+0.01%USDSEK+0.01%USDPLN+0.01%NZDSGD-0.01%EURPLN0.00%EURSEK0.00%EURDKK0.00%USOIL-1.36%GAGUSD+1.19%XAGUSD+1.19%UKOIL-1.15%XNGUSD-0.61%S1-0.57%HG1-0.57%W1-0.48%C1-0.45%GAUUSD+0.43%XAUUSD+0.43%COTTON-0.38%BTCUSD+0.13%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.13%ZECUSDT+0.76%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+1.32%XLMUSD+2.77%BCHUSDT+0.10%UNIUSD+0.17%LTCUSD+0.07%HBARUSDT+2.68%SUIUSD+2.04%TONUSD+15.77%TAOUSDT+1.84%AAVEUSD+0.02%DOTUSDT+4.88%ICPUSDT-1.11%ONDOUSDT+1.18%WLDUSDT+9.89%ARBUSDT+1.17%JUPUSDT+0.41%ATOMUSDT+3.31%INJUSDT-1.96%STXUSDT+22.43%FETUSDT+4.47%SEIUSDT+1.69%PYTHUSDT-1.21%TIAUSDT+3.33%IMXUSDT+4.00%GRTUSDT+1.83%OPUSDT+1.31%WIFUSDT+4.70%IOTAUSDT+7.34%POLUSDT-3.69%AXSUSDT+1.63%FARTCOINUSDT+0.60%EOSUSDT+4.44%DYDXUSDT+5.30%GALAUSDT+4.75%ORDIUSDT+3.07%NOTUSDT+3.60%RONINUSDT+3.21%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.08%GBPCHF+1.01%AUDUSD-1.00%USDCHF+0.91%GBPCAD+0.77%GBPNZD+0.70%USDCAD+0.70%GBPJPY+0.69%NZDUSD-0.64%EURGBP-0.63%USDJPY+0.60%USDTHB+0.58%EURUSD-0.56%PLNJPY+0.50%EURAUD+0.46%NOKJPY+0.43%AUDJPY-0.42%SGDJPY+0.42%GBPTRY+0.41%AUDNZD-0.36%EURCHF+0.35%AUDCAD-0.33%GBPHKD+0.32%USDTRY+0.29%GBPMXN-0.28%NZDCHF+0.28%CHFJPY-0.27%AUDSGD+0.23%AUDNOK+0.22%CADCHF+0.22%USDILS+0.16%AUDDKK+0.14%EURCAD+0.14%AUDCHF-0.11%NZDMXN-0.11%EURNZD+0.09%USDSGD+0.09%USDCNH-0.09%CADJPY-0.09%USDNOK+0.08%EURCNH+0.08%GBPUSD+0.08%EURSGD+0.08%EURNOK+0.07%NZDCAD+0.06%CHFSGD+0.06%CHFNOK+0.05%USDZAR+0.05%EURJPY+0.04%USDCOP-0.04%GBPSGD+0.04%EURHKD-0.04%EURCZK+0.03%USDHKD+0.03%GBPZAR-0.02%EURZAR+0.02%NZDJPY-0.02%CHFSEK-0.02%USDDKK+0.02%USDMXN+0.01%USDSEK+0.01%USDPLN+0.01%NZDSGD-0.01%EURPLN0.00%EURSEK0.00%EURDKK0.00%USOIL-1.36%GAGUSD+1.19%XAGUSD+1.19%UKOIL-1.15%XNGUSD-0.61%S1-0.57%HG1-0.57%W1-0.48%C1-0.45%GAUUSD+0.43%XAUUSD+0.43%COTTON-0.38%BTCUSD+0.13%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.13%ZECUSDT+0.76%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+1.32%XLMUSD+2.77%BCHUSDT+0.10%UNIUSD+0.17%LTCUSD+0.07%HBARUSDT+2.68%SUIUSD+2.04%TONUSD+15.77%TAOUSDT+1.84%AAVEUSD+0.02%DOTUSDT+4.88%ICPUSDT-1.11%ONDOUSDT+1.18%WLDUSDT+9.89%ARBUSDT+1.17%JUPUSDT+0.41%ATOMUSDT+3.31%INJUSDT-1.96%STXUSDT+22.43%FETUSDT+4.47%SEIUSDT+1.69%PYTHUSDT-1.21%TIAUSDT+3.33%IMXUSDT+4.00%GRTUSDT+1.83%OPUSDT+1.31%WIFUSDT+4.70%IOTAUSDT+7.34%POLUSDT-3.69%AXSUSDT+1.63%FARTCOINUSDT+0.60%EOSUSDT+4.44%DYDXUSDT+5.30%GALAUSDT+4.75%ORDIUSDT+3.07%NOTUSDT+3.60%RONINUSDT+3.21%
LP

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ • Healthcare

$312.37
+$2 (+0.6%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$310.52
Day Range$306.95 - $316.94
Avg. Volume (3M)258.1K
Market Cap$6.2B
P/E Ratio31.2
52 Week Range
$175.56$326.63
Next EarningsIn 35 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$63.6M100%
Gross Profitminus cost of goods$60.4M95%
Operating Incomeminus R&D and overhead$8.5M13%
Net Incomeminus taxes and the rest$48.5M76%

In plain terms: out of every $100 in revenue, Ligand Pharmaceuticals Incorporated keeps $76 as net profit.

Fundamentals & Financials

Revenue (TTM)
$290.5M
Net Income (TTM)
$197.2M
EPS (TTM)
$10.01
ROA (TTM)
9.02%
Current Ratio
31.18
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+38.4%Q1 2026$2.02
-11.4%Q2 2026$1.63
+17.9%Q3 2026$2.37
Next

Nov 5

in 35 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +17.9%

Ligand Pharmaceuticals topped consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, as revenue of $63.7 million topped the $61.3 million estimate, +3.9%, while adjusted EPS of $2.37 topped the $2.01 estimate, +17.9%. Revenue rose ~34% year over year to roughly $63.7 million from about $47.6 million a year ago, alongside GAAP operating income of about $8.6 million as operating margin stood near 14%. GAAP net income surged roughly 901% year over year to about $48.5 million, up from roughly $4.8 million a year ago. The quarter generated operating cash flow of roughly $24.0 million, and the company repurchased about $60.0 million of stock. Next-period consensus calls for EPS of $2.30 on revenue of $78.1 million.

View full earnings history

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biotechnology company that licenses and supports a portfolio of marketed medicines and formulation technology for pharmaceutical companies worldwide. Its business spans oncology, vaccines, central nervous system, anti-infective, cardiovascular, and bone-health products, and generated $268.1 million of revenue in FY2025.

Name
Ligand Pharmaceuticals Incorporated
CEO
Todd C. Davis
Website
www.ligand.com
Industry
Healthcare
Year Founded
1987
Employees
47

Today's Snapshot

AI-generated

The day ended with LGND 0.7% higher at 312.37, outperforming a weaker sector. Shares changed hands at about half as much again as its usual level. Ligand Pharmaceuticals signed a financing agreement with AvenCell Therapeutics, a biotech company.

Trading Volume

Above 10d avg 306.2K

478.1K

vs S&P 500 Today

Moderate Outperformance

+0.46%

Updated: September 30, 2026 at 20:19 UTC

Technical Indicators

6 Buy1 Neutral1 Sell
LGND presents a constructive technical picture with the stock near $312.37 and trading above its short-, medium- and long-term moving averages, including a markedly higher position than the 200-day average, indicating broad bullish alignment. Momentum readings are positive: MACD is on buy, CCI is strongly positive and momentum itself is elevated, while RSI sits in bullish territory. OBV is positive, supporting the advance, and ATR near 3.1% suggests moderate volatility. ADX around 19 indicates the trend lacks strong directional conviction but remains favorable. Technical takeaway: Buy — price, momentum and volume support a bullish posture.
All signals
  • EMA (5 indicators)$246.00 - $301.53
    Buy
  • RSI (14)67.41
    Neutral
  • Stochastic %K (14, 3, 3)91.03
    Sell
  • MACD Level (12, 26)5.59
    Buy

Peers & Related Assets

CRNXCrinetics Pharmaceuticals, Inc.
$84.950.0%
PRAXPraxis Precision Medicines, Inc.
$291.23+3.6%
MIRMMirum Pharmaceuticals, Inc.
$85.48-2.4%
VKTXViking Therapeutics, Inc.
$32.6+2.5%
ACADAcadia Pharmaceuticals Inc.
$20.15-0.3%
DYNDyne Therapeutics, Inc.
$16.11-0.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.